HYPF yields 2000000.00% · ABBV yields 3.06%● Live data
📍 HYPF pulled ahead of the other in Year 1
Combined, HYPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HYPF + ABBV for your $10,000?
Hypower Fuel, Inc., a development stage company, focuses on developing and supplying alternative fuel sources in North America. It specializes in hydrogen production and hydrogen related products. The company developed proprietary technologies to reduce dependence on fossil fuels, as well as to eliminate harmful toxic emissions that threaten environment. Its products include the Hydro Power Pak (HPP), a retrofit hydrogen insertion device for use on tractor trailer rigs, as well as on stationary diesel engines to enhance fuel economy, reduce harmful emissions, and enhance engine performance and horsepower; and Hydrogen Reactor under development to produce hydrogen on board to power a gasoline engine. Hypower Fuel's product portfolio also consists of an interface control module (ICM) to work in either a stand-alone application with an engine's fuel delivery system or in conjunction with the HPP under programming and testing stage for applications in the trucking industry. ICM's capabilities include enhanced horsepower rating, monitoring engine operations, data acquisition, and global positioning systems. The company also developed a manufacturing process to produce an organic diesel fuel lubrication additive, Bio-Lube, for enhancing lubricity to protect diesel fuel injectors and pumps; and replacing hydrocarbon two stroke oils to reduce harmful toxic emissions and provide enhanced lubrication. Hypower Fuel, Inc. was incorporated in 1987 and is headquartered in High River, Canada.
Full HYPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.